EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways

Waipan Chan iD, Yuqi M Cao iD, Xiang Zhao iD, Edward C Schrom iD, Dongya Jia iD, Jian Song iD, Leah V Sibener iD, Shen Dong iD, Ricardo A Fernandes iD, Clinton J Bradfield iD, Margery Smelkinson iD, Juraj Kabat iD und 4 weitere

Journal of Experimental Medicine · 04.12.2023 · 220 (12)

DOI: 10.1084/jem.20231242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 05.10.2023. Verfasst von Waipan Chan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Signal Transduction. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint blockade revolutionized cancer therapy, but we still lack a quantitative, mechanistic understanding of how inhibitory receptors affect diverse signaling pathways. To address this issue, we developed and applied a fluorescent intracellular live multiplex signal transduction activity reporter (FILMSTAR) system to analyze PD-1-induced suppressive effects. These studies identified pathways triggered solely by TCR or requiring both TCR and CD28 inputs. Using presenting cells differing in PD-L1 and CD80 expression while displaying TCR ligands of distinct potency, we found that PD-1-mediated inhibition primarily targets TCR-linked signals in a manner highly sensitive to peptide ligand quality. These findings help resolve discrepancies in existing data about the site(s) of PD-1 inhibition in T cells while emphasizing the importance of neoantigen potency in controlling the effects of checkpoint therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorSignal TransductionLigandsT-LymphocytesReceptors, Antigen, T-CellB7-H1 Antigen

Substanzen

Programmed Cell Death 1 ReceptorLigandsReceptors, Antigen, T-CellB7-H1 Antigen

Autor:innen und Institutionen

  • Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Department of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Immunodynamics Group, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Signaling Systems Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Biological Imaging Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Howard Hughes Medical Institute, Stanford University School of Medicine , Stanford, CA, USA.

ORCID-Profile: Waipan Chan, Yuqi M Cao, Xiang Zhao, Edward C Schrom, Dongya Jia, Jian Song, Leah V Sibener, Shen Dong, Ricardo A Fernandes, Clinton J Bradfield, Margery Smelkinson, Juraj Kabat, Jyh Liang Hor, Grégoire Altan-Bonnet, K Christopher Garcia, Ronald N Germain

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • Howard Hughes Medical Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Parker Foundation
  • National Cancer Institute

Zitieren

APA

Chan, W., Cao, Y. M., Zhao, X., Schrom, E. C., Jia, D., Song, J., Sibener, L. V., Dong, S., Fernandes, R. A., Bradfield, C. J., Smelkinson, M., Kabat, J., Hor, J. L., Altan-Bonnet, G., Garcia, K. C., & Germain, R. N. (2023). TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways. Journal of Experimental Medicine, 220(12). https://doi.org/10.1084/jem.20231242

Vancouver

Chan W, Cao YM, Zhao X, Schrom EC, Jia D, Song J, et al. TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways. Journal of Experimental Medicine. 2023;220(12). doi:10.1084/jem.20231242

BibTeX
@article{Chan2023,
  author = {Chan, Waipan and Cao, Yuqi M and Zhao, Xiang and Schrom, Edward C and Jia, Dongya and Song, Jian and Sibener, Leah V and Dong, Shen and Fernandes, Ricardo A and Bradfield, Clinton J and Smelkinson, Margery and Kabat, Juraj and Hor, Jyh Liang and Altan-Bonnet, Grégoire and Garcia, K Christopher and Germain, Ronald N},
  title = {TCR ligand potency differentially impacts PD-1 inhibitory effects on diverse signaling pathways},
  journal = {Journal of Experimental Medicine},
  year = {2023},
  volume = {220},
  number = {12},
  doi = {10.1084/jem.20231242}
}
Kostenlos starten →